p53-Independent, Normal Stem Cell Sparing Epigenetic Differentiation Therapy for Myeloid and Other Malignancies
- 29 February 2012
- journal article
- review article
- Published by Elsevier BV in Seminars in Oncology
- Vol. 39 (1), 97-108
- https://doi.org/10.1053/j.seminoncol.2011.11.011
Abstract
No abstract availableKeywords
This publication has 131 references indexed in Scilit:
- CpG methylation patterns and decitabine treatment response in acute myeloid leukemia cells and normal hematopoietic precursorsLeukemia, 2011
- MLL-Rearranged Leukemia Is Dependent on Aberrant H3K79 Methylation by DOT1LCancer Cell, 2011
- p53 Independent epigenetic-differentiation treatment in xenotransplant models of acute myeloid leukemiaLeukemia, 2011
- Exome sequencing identifies frequent mutation of the SWI/SNF complex gene PBRM1 in renal carcinomaNature, 2011
- A Myc Network Accounts for Similarities between Embryonic Stem and Cancer Cell Transcription ProgramsCell, 2010
- Covalent histone modifications — miswritten, misinterpreted and mis-erased in human cancersNature Reviews Cancer, 2010
- Efficient tumour formation by single human melanoma cellsNature, 2008
- Human acute leukemia cells injected in NOD/LtSz‐scid/IL‐2Rγ null mice generate a faster and more efficient disease compared to other NOD/scid‐related strainsInternational Journal of Cancer, 2008
- Survival advantage with decitabine versus intensive chemotherapy in patients with higher risk myelodysplastic syndromeCancer, 2007
- Prospective identification of tumorigenic breast cancer cellsProceedings of the National Academy of Sciences of the United States of America, 2003